Find a Clinical Trial

A clinical trial investigating BNT113 in combination with pembrolizumab versus pembrolizumab alone for patients with a form of head and neck cancer positive for human papilloma virus 16 and expressing the protein PD-L1

An open-label Phase II randomized trial of BNT113 in combination with
pembrolizumab versus pembrolizumab monotherapy as a first line therapy in
patients with unresectable recurrent, or metastatic Head and Neck
Squamous Cell Carcinoma (HNSCC) which is positive for human papilloma
virus 16 (HPV16+) and expresses PD-L1

18+

Learn more

EA3191

EA3191 - A Phase II Randomized Trial of Adjuvant Therapy with Pembrolizumab after Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma with High Risk Features

18-79

Learn more